TriangleNCT02561962 · OUTCOME
Maximum Observed Concentration (Cmax) of AMG 224 Conjugated Antibody, Total Anti-B-cell Maturation Antigen (Anti-BCMA) Antibody, and Total Unconjugated DM1
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- µg/mL
- Interval / dispersion
- Full Range
- Time frame
- AMG 224 and anti-BCMA antibody: pre-dose, 0.5 hours, end of infusion (EOI), 4 hours, 24 hours, 96 hours, 168 hours, and 336 hours post-dose (Cycles 1 + 2); DM1: pre-dose, 0.5 hours, EOI, 4 hours, 24 hours, and 96 hours post-dose (Cycles 1 + 2)
What was measured
Cmax of AMG 224 conjugated antibody, total anti-BCMA antibody and total unconjugated DM1 was measured. DM1 is a semi-synthetic derivative of the ansamycin antibiotic, maytansine conjugated to the non-cleavable linker 4-\[N-maleimidomethyl\] cyclohexane-1-carboxylate conjugated to lysine residues in the antibody (MCC).
Analysis population: The pharmacokinetic (PK) parameter analysis set included participants who received at least 1 dose of AMG 224 and for whom PK parameters could be adequately estimated.
Groups in this outcome
Dose Exploration: AMG 224 Dose A
Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose B
Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose C
Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose D
Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose E
Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose F
Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Exploration: AMG 224 Dose G
Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Dose Expansion: AMG 224 3 mg/kg
All participants in Dose Expansion who had prior treatment or no prior treatment with a CD38-targeting antibody were administered the MTD of AMG 224 identified in the dose escalation as 3 mg/kg. AMG 224 was administered as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.
| Group | Source count |
|---|---|
| Dose Exploration: AMG 224 Dose A | 3 |
| Dose Exploration: AMG 224 Dose B | 3 |
| Dose Exploration: AMG 224 Dose C | 3 |
| Dose Exploration: AMG 224 Dose D | 3 |
| Dose Exploration: AMG 224 Dose E | 5 |
| Dose Exploration: AMG 224 Dose F | 6 |
| Dose Exploration: AMG 224 Dose G | 5 |
| Dose Expansion: AMG 224 3 mg/kg | 10 |
Reported measurements
AMG 224 Conjugated Antibody after Cycle 1
| Group | Source count |
|---|---|
| Dose Exploration: AMG 224 Dose A | 3 |
| Dose Exploration: AMG 224 Dose B | 3 |
| Dose Exploration: AMG 224 Dose C | 3 |
| Dose Exploration: AMG 224 Dose D | 3 |
| Dose Exploration: AMG 224 Dose E | 5 |
| Dose Exploration: AMG 224 Dose F | 5 |
| Dose Exploration: AMG 224 Dose G | 5 |
| Dose Expansion: AMG 224 3 mg/kg | 10 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Dose Exploration: AMG 224 Dose A | 11.4 | Not reported | 5.99 | 14.3 | Not reported |
| Dose Exploration: AMG 224 Dose B | 22.0 | Not reported | 16.4 | 28.9 | Not reported |
| Dose Exploration: AMG 224 Dose C | 25.3 | Not reported | 20.0 | 31.2 | Not reported |
| Dose Exploration: AMG 224 Dose D | 32.9 | Not reported | 19.8 | 42.9 | Not reported |
| Dose Exploration: AMG 224 Dose E | 37.5 | Not reported | 6.32 | 67.7 | Not reported |
| Dose Exploration: AMG 224 Dose F | 54.2 | Not reported | 45.1 | 74.4 | Not reported |
| Dose Exploration: AMG 224 Dose G | 61.9 | Not reported | 47.1 | 75.5 | Not reported |
| Dose Expansion: AMG 224 3 mg/kg | 55.8 | Not reported | 39.9 | 80.9 | Not reported |
AMG 224 Conjugated Antibody after Cycle 2
| Group | Source count |
|---|---|
| Dose Exploration: AMG 224 Dose A | 3 |
| Dose Exploration: AMG 224 Dose B | 3 |
| Dose Exploration: AMG 224 Dose C | 3 |
| Dose Exploration: AMG 224 Dose D | 3 |
| Dose Exploration: AMG 224 Dose E | 3 |
| Dose Exploration: AMG 224 Dose F | 5 |
| Dose Exploration: AMG 224 Dose G | 2 |
| Dose Expansion: AMG 224 3 mg/kg | 8 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Dose Exploration: AMG 224 Dose A | 11.5 | Not reported | 8.26 | 15.4 | Not reported |
| Dose Exploration: AMG 224 Dose B | 29.3 | Not reported | 20.6 | 44.6 | Not reported |
| Dose Exploration: AMG 224 Dose C | 31.0 | Not reported | 26.4 | 39.0 | Not reported |
| Dose Exploration: AMG 224 Dose D | 38.5 | Not reported | 24.0 | 51.5 | Not reported |
| Dose Exploration: AMG 224 Dose E | 40.1 | Not reported | 29.0 | 53.8 | Not reported |
| Dose Exploration: AMG 224 Dose F | 60.8 | Not reported | 51.2 | 84.7 | Not reported |
| Dose Exploration: AMG 224 Dose G | 78.7 | Not reported | 67.4 | 89.9 | Not reported |
| Dose Expansion: AMG 224 3 mg/kg | 73.3 | Not reported | 46.6 | 89.9 | Not reported |
Total Anti-BCMA Antibody after Cycle 1
| Group | Source count |
|---|---|
| Dose Exploration: AMG 224 Dose A | 3 |
| Dose Exploration: AMG 224 Dose B | 3 |
| Dose Exploration: AMG 224 Dose C | 3 |
| Dose Exploration: AMG 224 Dose D | 3 |
| Dose Exploration: AMG 224 Dose E | 5 |
| Dose Exploration: AMG 224 Dose F | 5 |
| Dose Exploration: AMG 224 Dose G | 5 |
| Dose Expansion: AMG 224 3 mg/kg | 10 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Dose Exploration: AMG 224 Dose A | 11.9 | Not reported | 7.09 | 14.5 | Not reported |
| Dose Exploration: AMG 224 Dose B | 23.9 | Not reported | 20.4 | 30.5 | Not reported |
| Dose Exploration: AMG 224 Dose C | 25.3 | Not reported | 21.4 | 29.8 | Not reported |
| Dose Exploration: AMG 224 Dose D | 34.7 | Not reported | 19.3 | 47.2 | Not reported |
| Dose Exploration: AMG 224 Dose E | 40.2 | Not reported | 8.72 | 75.8 | Not reported |
| Dose Exploration: AMG 224 Dose F | 52.4 | Not reported | 49.6 | 55.5 | Not reported |
| Dose Exploration: AMG 224 Dose G | 67.7 | Not reported | 50.4 | 84.9 | Not reported |
| Dose Expansion: AMG 224 3 mg/kg | 52.1 | Not reported | 33.7 | 73.8 | Not reported |
Total Anti-BCMA Antibody after Cycle 2
| Group | Source count |
|---|---|
| Dose Exploration: AMG 224 Dose A | 3 |
| Dose Exploration: AMG 224 Dose B | 3 |
| Dose Exploration: AMG 224 Dose C | 3 |
| Dose Exploration: AMG 224 Dose D | 3 |
| Dose Exploration: AMG 224 Dose E | 5 |
| Dose Exploration: AMG 224 Dose F | 5 |
| Dose Exploration: AMG 224 Dose G | 2 |
| Dose Expansion: AMG 224 3 mg/kg | 8 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Dose Exploration: AMG 224 Dose A | 11.9 | Not reported | 9.84 | 13.5 | Not reported |
| Dose Exploration: AMG 224 Dose B | 34.6 | Not reported | 22.5 | 51.8 | Not reported |
| Dose Exploration: AMG 224 Dose C | 33.2 | Not reported | 28.9 | 40.5 | Not reported |
| Dose Exploration: AMG 224 Dose D | 41.6 | Not reported | 25.0 | 56.2 | Not reported |
| Dose Exploration: AMG 224 Dose E | 45.3 | Not reported | 34.6 | 63.9 | Not reported |
| Dose Exploration: AMG 224 Dose F | 63.4 | Not reported | 55.5 | 72.4 | Not reported |
| Dose Exploration: AMG 224 Dose G | 79.6 | Not reported | 50.2 | 109 | Not reported |
| Dose Expansion: AMG 224 3 mg/kg | 62.4 | Not reported | 39.0 | 77.2 | Not reported |
DM1 after Cycle 1
| Group | Source count |
|---|---|
| Dose Exploration: AMG 224 Dose A | 3 |
| Dose Exploration: AMG 224 Dose B | 3 |
| Dose Exploration: AMG 224 Dose C | 3 |
| Dose Exploration: AMG 224 Dose D | 3 |
| Dose Exploration: AMG 224 Dose E | 5 |
| Dose Exploration: AMG 224 Dose F | 6 |
| Dose Exploration: AMG 224 Dose G | 5 |
| Dose Expansion: AMG 224 3 mg/kg | 10 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Dose Exploration: AMG 224 Dose A | 0.00 | Not reported | 0.00 | 0.00 | Not reported |
| Dose Exploration: AMG 224 Dose B | 0.00 | Not reported | 0.00 | 0.00 | Not reported |
| Dose Exploration: AMG 224 Dose C | 0.000312 | Not reported | 0.00 | 0.000501 | Not reported |
| Dose Exploration: AMG 224 Dose D | 0.000549 | Not reported | 0.000445 | 0.000693 | Not reported |
| Dose Exploration: AMG 224 Dose E | 0.00131 | Not reported | 0.000568 | 0.00210 | Not reported |
| Dose Exploration: AMG 224 Dose F | 0.00141 | Not reported | 0.000967 | 0.00192 | Not reported |
| Dose Exploration: AMG 224 Dose G | 0.00155 | Not reported | 0.00123 | 0.00201 | Not reported |
| Dose Expansion: AMG 224 3 mg/kg | 0.00149 | Not reported | 0.000924 | 0.00210 | Not reported |
DM1 after Cycle 2
| Group | Source count |
|---|---|
| Dose Exploration: AMG 224 Dose A | 3 |
| Dose Exploration: AMG 224 Dose B | 3 |
| Dose Exploration: AMG 224 Dose C | 3 |
| Dose Exploration: AMG 224 Dose D | 3 |
| Dose Exploration: AMG 224 Dose E | 3 |
| Dose Exploration: AMG 224 Dose F | 5 |
| Dose Exploration: AMG 224 Dose G | 2 |
| Dose Expansion: AMG 224 3 mg/kg | 8 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Dose Exploration: AMG 224 Dose A | 0.00 | Not reported | 0.00 | 0.00 | Not reported |
| Dose Exploration: AMG 224 Dose B | 0.000119 | Not reported | 0.00 | 0.000356 | Not reported |
| Dose Exploration: AMG 224 Dose C | 0.000414 | Not reported | 0.000297 | 0.000590 | Not reported |
| Dose Exploration: AMG 224 Dose D | 0.000654 | Not reported | 0.000423 | 0.000913 | Not reported |
| Dose Exploration: AMG 224 Dose E | 0.000872 | Not reported | 0.000658 | 0.00121 | Not reported |
| Dose Exploration: AMG 224 Dose F | 0.00172 | Not reported | 0.00141 | 0.00264 | Not reported |
| Dose Exploration: AMG 224 Dose G | 0.00161 | Not reported | 0.00151 | 0.00170 | Not reported |
| Dose Expansion: AMG 224 3 mg/kg | 0.00177 | Not reported | 0.00140 | 0.00242 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 5.99
- upper Limit
- 14.3
- value
- 11.4
- group Id
- OG001
- lower Limit
- 16.4
- upper Limit
- 28.9
- value
- 22.0
- group Id
- OG002
- lower Limit
- 20.0
- upper Limit
- 31.2
- value
- 25.3
- group Id
- OG003
- lower Limit
- 19.8
- upper Limit
- 42.9
- value
- 32.9
- group Id
- OG004
- lower Limit
- 6.32
- upper Limit
- 67.7
- value
- 37.5
- group Id
- OG005
- lower Limit
- 45.1
- upper Limit
- 74.4
- value
- 54.2
- group Id
- OG006
- lower Limit
- 47.1
- upper Limit
- 75.5
- value
- 61.9
- group Id
- OG007
- lower Limit
- 39.9
- upper Limit
- 80.9
- value
- 55.8
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 3
- group Id
- OG002
- value
- 3
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 5
- group Id
- OG005
- value
- 5
- group Id
- OG006
- value
- 5
- group Id
- OG007
- value
- 10
- units
- Participants
- title
- AMG 224 Conjugated Antibody after Cycle 1
- categories
- measurements
- group Id
- OG000
- lower Limit
- 8.26
- upper Limit
- 15.4
- value
- 11.5
- group Id
- OG001
- lower Limit
- 20.6
- upper Limit
- 44.6
- value
- 29.3
- group Id
- OG002
- lower Limit
- 26.4
- upper Limit
- 39.0
- value
- 31.0
- group Id
- OG003
- lower Limit
- 24.0
- upper Limit
- 51.5
- value
- 38.5
- group Id
- OG004
- lower Limit
- 29.0
- upper Limit
- 53.8
- value
- 40.1
- group Id
- OG005
- lower Limit
- 51.2
- upper Limit
- 84.7
- value
- 60.8
- group Id
- OG006
- lower Limit
- 67.4
- upper Limit
- 89.9
- value
- 78.7
- group Id
- OG007
- lower Limit
- 46.6
- upper Limit
- 89.9
- value
- 73.3
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 3
- group Id
- OG002
- value
- 3
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 3
- group Id
- OG005
- value
- 5
- group Id
- OG006
- value
- 2
- group Id
- OG007
- value
- 8
- units
- Participants
- title
- AMG 224 Conjugated Antibody after Cycle 2
- categories
- measurements
- group Id
- OG000
- lower Limit
- 7.09
- upper Limit
- 14.5
- value
- 11.9
- group Id
- OG001
- lower Limit
- 20.4
- upper Limit
- 30.5
- value
- 23.9
- group Id
- OG002
- lower Limit
- 21.4
- upper Limit
- 29.8
- value
- 25.3
- group Id
- OG003
- lower Limit
- 19.3
- upper Limit
- 47.2
- value
- 34.7
- group Id
- OG004
- lower Limit
- 8.72
- upper Limit
- 75.8
- value
- 40.2
- group Id
- OG005
- lower Limit
- 49.6
- upper Limit
- 55.5
- value
- 52.4
- group Id
- OG006
- lower Limit
- 50.4
- upper Limit
- 84.9
- value
- 67.7
- group Id
- OG007
- lower Limit
- 33.7
- upper Limit
- 73.8
- value
- 52.1
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 3
- group Id
- OG002
- value
- 3
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 5
- group Id
- OG005
- value
- 5
- group Id
- OG006
- value
- 5
- group Id
- OG007
- value
- 10
- units
- Participants
- title
- Total Anti-BCMA Antibody after Cycle 1
- categories
- measurements
- group Id
- OG000
- lower Limit
- 9.84
- upper Limit
- 13.5
- value
- 11.9
- group Id
- OG001
- lower Limit
- 22.5
- upper Limit
- 51.8
- value
- 34.6
- group Id
- OG002
- lower Limit
- 28.9
- upper Limit
- 40.5
- value
- 33.2
- group Id
- OG003
- lower Limit
- 25.0
- upper Limit
- 56.2
- value
- 41.6
- group Id
- OG004
- lower Limit
- 34.6
- upper Limit
- 63.9
- value
- 45.3
- group Id
- OG005
- lower Limit
- 55.5
- upper Limit
- 72.4
- value
- 63.4
- group Id
- OG006
- lower Limit
- 50.2
- upper Limit
- 109
- value
- 79.6
- group Id
- OG007
- lower Limit
- 39.0
- upper Limit
- 77.2
- value
- 62.4
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 3
- group Id
- OG002
- value
- 3
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 5
- group Id
- OG005
- value
- 5
- group Id
- OG006
- value
- 2
- group Id
- OG007
- value
- 8
- units
- Participants
- title
- Total Anti-BCMA Antibody after Cycle 2
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0.00
- upper Limit
- 0.00
- value
- 0.00
- group Id
- OG001
- lower Limit
- 0.00
- upper Limit
- 0.00
- value
- 0.00
- group Id
- OG002
- lower Limit
- 0.00
- upper Limit
- 0.000501
- value
- 0.000312
- group Id
- OG003
- lower Limit
- 0.000445
- upper Limit
- 0.000693
- value
- 0.000549
- group Id
- OG004
- lower Limit
- 0.000568
- upper Limit
- 0.00210
- value
- 0.00131
- group Id
- OG005
- lower Limit
- 0.000967
- upper Limit
- 0.00192
- value
- 0.00141
- group Id
- OG006
- lower Limit
- 0.00123
- upper Limit
- 0.00201
- value
- 0.00155
- group Id
- OG007
- lower Limit
- 0.000924
- upper Limit
- 0.00210
- value
- 0.00149
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 3
- group Id
- OG002
- value
- 3
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 5
- group Id
- OG005
- value
- 6
- group Id
- OG006
- value
- 5
- group Id
- OG007
- value
- 10
- units
- Participants
- title
- DM1 after Cycle 1
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0.00
- upper Limit
- 0.00
- value
- 0.00
- group Id
- OG001
- lower Limit
- 0.00
- upper Limit
- 0.000356
- value
- 0.000119
- group Id
- OG002
- lower Limit
- 0.000297
- upper Limit
- 0.000590
- value
- 0.000414
- group Id
- OG003
- lower Limit
- 0.000423
- upper Limit
- 0.000913
- value
- 0.000654
- group Id
- OG004
- lower Limit
- 0.000658
- upper Limit
- 0.00121
- value
- 0.000872
- group Id
- OG005
- lower Limit
- 0.00141
- upper Limit
- 0.00264
- value
- 0.00172
- group Id
- OG006
- lower Limit
- 0.00151
- upper Limit
- 0.00170
- value
- 0.00161
- group Id
- OG007
- lower Limit
- 0.00140
- upper Limit
- 0.00242
- value
- 0.00177
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 3
- group Id
- OG002
- value
- 3
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 3
- group Id
- OG005
- value
- 5
- group Id
- OG006
- value
- 2
- group Id
- OG007
- value
- 8
- units
- Participants
- title
- DM1 after Cycle 2
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 3
- group Id
- OG002
- value
- 3
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 5
- group Id
- OG005
- value
- 6
- group Id
- OG006
- value
- 5
- group Id
- OG007
- value
- 10
- units
- Participants
- description
- Cmax of AMG 224 conjugated antibody, total anti-BCMA antibody and total unconjugated DM1 was measured. DM1 is a semi-synthetic derivative of the ansamycin antibiotic, maytansine conjugated to the non-cleavable linker 4-\[N-maleimidomethyl\] cyclohexane-1-carboxylate conjugated to lysine residues in the antibody (MCC).
- dispersion Type
- Full Range
- groups
- description
- Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.
- id
- OG000
- title
- Dose Exploration: AMG 224 Dose A
- description
- Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
- id
- OG001
- title
- Dose Exploration: AMG 224 Dose B
- description
- Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
- id
- OG002
- title
- Dose Exploration: AMG 224 Dose C
- description
- Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
- id
- OG003
- title
- Dose Exploration: AMG 224 Dose D
- description
- Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
- id
- OG004
- title
- Dose Exploration: AMG 224 Dose E
- description
- Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
- id
- OG005
- title
- Dose Exploration: AMG 224 Dose F
- description
- Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
- id
- OG006
- title
- Dose Exploration: AMG 224 Dose G
- description
- All participants in Dose Expansion who had prior treatment or no prior treatment with a CD38-targeting antibody were administered the MTD of AMG 224 identified in the dose escalation as 3 mg/kg. AMG 224 was administered as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.
- id
- OG007
- title
- Dose Expansion: AMG 224 3 mg/kg
- param Type
- MEAN
- population Description
- The pharmacokinetic (PK) parameter analysis set included participants who received at least 1 dose of AMG 224 and for whom PK parameters could be adequately estimated.
- reporting Status
- POSTED
- time Frame
- AMG 224 and anti-BCMA antibody: pre-dose, 0.5 hours, end of infusion (EOI), 4 hours, 24 hours, 96 hours, 168 hours, and 336 hours post-dose (Cycles 1 + 2); DM1: pre-dose, 0.5 hours, EOI, 4 hours, 24 hours, and 96 hours post-dose (Cycles 1 + 2)
- title
- Maximum Observed Concentration (Cmax) of AMG 224 Conjugated Antibody, Total Anti-B-cell Maturation Antigen (Anti-BCMA) Antibody, and Total Unconjugated DM1
- type
- SECONDARY
- unit Of Measure
- µg/mL
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice